Patents by Inventor Meinhard Hasslacher
Meinhard Hasslacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230242897Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: ApplicationFiled: April 11, 2023Publication date: August 3, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Publication number: 20230241139Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.Type: ApplicationFiled: January 13, 2023Publication date: August 3, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian FIEDLER, Eva FRITSCHER, Meinhard HASSLACHER, Dominik MITTERGRADNEGGER, Tanvir TABISH
-
Patent number: 11661593Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.Type: GrantFiled: December 16, 2014Date of Patent: May 30, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
-
Patent number: 11583563Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.Type: GrantFiled: November 3, 2017Date of Patent: February 21, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Eva Fritscher, Meinhard Hasslacher, Dominik Mittergradnegger, Tanvir Tabish
-
Publication number: 20220275058Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.Type: ApplicationFiled: March 7, 2022Publication date: September 1, 2022Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
-
Publication number: 20220267796Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken at room temperature, and AAV is eluted from the affinity resin at a lower temperature. Various buffers are disclosed for use in the wash steps and elution.Type: ApplicationFiled: June 26, 2020Publication date: August 25, 2022Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian FIEDLER, Marcus SCHEINDEL, Meinhard HASSLACHER, Jadranka KOEHN
-
Patent number: 11421202Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.Type: GrantFiled: March 12, 2020Date of Patent: August 23, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Wolfgang Mundt, Artur Mitterer, Manfred Reiter, Meinhard Hasslacher, Leopold Grillberger, Thomas Kreil
-
Patent number: 11299533Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.Type: GrantFiled: June 22, 2018Date of Patent: April 12, 2022Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
-
Patent number: 11254921Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: GrantFiled: June 16, 2020Date of Patent: February 22, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Publication number: 20220041693Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: ApplicationFiled: February 8, 2021Publication date: February 10, 2022Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20210338752Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: ApplicationFiled: April 12, 2021Publication date: November 4, 2021Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian FIEDLER, Leopold Grillberger, Meinhard Hasslacher, Barbara Kraus, Dominik Mittergradnegger, Stefan Reuberger, Horst Schafhauser, Marian Bendik
-
Patent number: 11000561Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: GrantFiled: November 3, 2017Date of Patent: May 11, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Christian Fiedler, Leopold Grillberger, Meinhard Hasslacher, Barbara Kraus, Dominik Mittergradnegger, Stefan Reuberger, Horst Schafhauser, Marian Bendik
-
Patent number: 10934340Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: GrantFiled: March 20, 2019Date of Patent: March 2, 2021Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20200332266Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken, and AAV is eluted from the affinity resin. Various buffers are disclosed for use in the wash steps and elution.Type: ApplicationFiled: December 27, 2018Publication date: October 22, 2020Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Christian FIEDLER, Meinhard HASSLACHER, Jadranka KOEHN
-
Publication number: 20200308566Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Publication number: 20200277565Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.Type: ApplicationFiled: March 12, 2020Publication date: September 3, 2020Applicants: Baxalta Incorporated, Baxalta GmbHInventors: Wolfgang MUNDT, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KREIL
-
Patent number: 10723761Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.Type: GrantFiled: June 6, 2017Date of Patent: July 28, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
-
Patent number: 10724024Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.Type: GrantFiled: September 8, 2018Date of Patent: July 28, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
-
Publication number: 20190382467Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).Type: ApplicationFiled: March 20, 2019Publication date: December 19, 2019Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
-
Publication number: 20190365835Abstract: Provided herein are methods of producing an adeno-associated virus (AAV) product, methods of purifying adeno-associated virus, and methods of purifying full AAV capsids from a concentrated AAV fraction comprising empty AAV capsids and full AAV capsids.Type: ApplicationFiled: November 3, 2017Publication date: December 5, 2019Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Christian FIEDLER, Leopold GRILLBERGER, Meinhard HASSLACHER, Barbara KRAUS, Dominik MITTERGRADNEGGER, Stefan REUBERGER, Horst SCHAFHAUSER, Marian BENDIK